Small Cap Feast

Small Cap Feast – 22nd March 2017

Dish of the Day:

No AIM Joiners Today

 

Off the Menu:

No AIM Leavers Today

What’s Cooking in the IPO Kitchen?

Integumen— Schedule 1 from the personal health company developing and commercialising technology and products for the human integumentary system. Raising £2.16m at 5p. Expected market cap £8.16m. Admission expected 5 April.

Sentinel—Investment company expecting NEX admission/introduction on 24 March. £636k raised pre-IPO.

BioPharma Credit—Expected Gross Initial Acquisition Proceeds now c.$338m. Gross Cash Proceeds capped at $423m with placing and open offer. Results expected 23 March with admission  now due 30 march.

Tufton Oceanic Assets- The Company intends to invest in a diversified portfolio of second hand commercial sea-going vessels where the Investment Manager believes that an attractive opportunity exists in shipping. $150m raise. Admission 3 April.

 

Breakfast Buffet

ECSC (ECSC.L) 265p £23.83m

15 mth results to December 2016 from the provider of cyber security. All comps are for a 12 month period. Rev of £4.5m from £2.65m. Adjusted EBITDA of £630k.  Reported loss of £517k including exceptional IPO costs. LFL revenue growth of 35% in managed services and 24% in consultancy. Net cash of £5m. “Following on from a strong 2016, our ongoing plan is to significantly scale the business in 2017. The Board assesses the readiness of our clients to buy our services and this, together with the growth in the sector generally, make scaling the business at this time the right approach for ECSC”. Headcount up to 98 from 57 at IPO. FY17E rev of £11m growing to £11.6m for FY18E.

Van Elle Holdings (VANL.L) 90.15p £72.83m

Trading update from the geotechnical contractor offering a wide range of ground engineering techniques and services to customers in a variety of UK construction end markets. Overall trading in Q3, which included significant levels of activity in December and January, was in line with the Board’s expectations. As a result, for the nine months to Jan 2017, the Group delivered total revenues of £70.8 million, representing growth of 16.4 per cent. Conditions in Van Elle’s end markets remained satisfactory throughout the period and the Group continued to focus on generating improving returns through strong operational execution. Some Q4  contracts delayed into next year. Now expecting FY revenue of £93m some 5% below prior expectations. Unlikely to  effect final dividend. Some caution on rail activity for 2018. FYAp18E rev £112m likely to come back a bit.

 

Rose Petroleum (ROSE.L) 0.13p £4.71m

The natural resource business, has  updated on its Paradox acreage position, with the grant of a five year lease extension on State lands, within the Gunnison Valley Unit, Grand County, Utah.  The Federal Unit consists of a total of 64,482.97 acres of which Rose is earning a 75% working interest in 52,315.51 net acres.   “Due to the progress we are making on the 3D seismic shoot programme, the State has agreed to extend the leases which is a very encouraging show of support. We look forward to updating the market further on the seismic permitting process in due course.”

 

Haydale Graphene (HAYD.L) 166p £29.28m

HY Dec 16 results from the global technologies and materials group that facilitates the integration of nanomaterials into the next generation of commercial technologies and industrial materials. Total income up 90% year-on-year to £1.5 million. Cash at period end of £1.1 million pending receipt og £3.3m strategic investment by Everpower which could also open up big opportunities in China. “This half year has seen the successful acquisition and integration of two businesses that substantially increases our international reach and broadens our speciality nanomaterials offering. “

 

Inland Homes (INL.L) 63.5p £128.3m

The leading brownfield regeneration specialist and housebuilder with a focus on the South and South East of England, has secured planning permission to develop 239 residential units and 15,845 sq ft of commercial space at its Lily’s Walk site in High Wycombe, representing a GDV of £75 million. Resolutions to grant planning consent have been secured for a further 992 residential units on sites in Buckinghamshire and Hampshire, including the major development at Chapel Riverside in Southampton.

 

Octagonal (OCT.L) 2.95p £16.53m

Octagonal has updated on a new business opportunity being developed by its wholly owned subsidiary, Global Investment Strategy UK Limited. The opportunity is in line with the Group’s strategy of utilising its FCA Permissions to diversify and grow revenues through earnings enhancing projects. GIS has incorporated Synergis Capital Ltd as a majority owned subsidiary (“SynerGIS”) for the purpose of issuing an investment bond. SynerGIS has been established to provide commercial asset backed lending and its operations will be independent on the activities of GIS. It is proposed that the SynergisBond be listed on the Irish Stock Exchange and, as such, a draft Prospectus has now been submitted to the Central Bank of Ireland for review.

 

Futura Medical (FUM.L) 56p £67.34m

The innovative healthcare company focused on advanced transdermal technology, announced that it has signed an exclusive licensing agreement with F Lima SA  for the marketing and distribution of CSD500, Futura’s novel erectogenic condom, in Portugal. It is expected that F Lima, an established Portuguese business that distributes consumer brands into a broad range of retail outlets including supermarkets and pharmacies, will launch CSD500 under the Blue Diamond brand name as soon as practicable.

 

Randall & Quilter (RQIH.L) 123.5p £89.07m

Acquisition of ICDC, Ltd. a captive insurer of an American Fortune 500 company. The Company, originally incorporated under the laws of Bermuda, was re-domiciled in Vermont effective June 30, 2015. The company reinsured workers’ compensation, commercial general liability, business auto liability, business auto physical damage and property risks of the parent. ICDC, which is in run-off, had a total net asset value of $7.95m as at 31 December 2016 with reserves estimated at circa $2.76m. “This transaction demonstrates our ongoing commitment to continue to acquire legacy insurance assets and also continues to expand our acquisition activity in the North America, Bermuda and the Caribbean region”.

 

Netalogue Technologies(NEX:NTLP) 4.65p £2.3m

Netalogue has signed a partnership deal with Sage in support of the X3 ERP platform. This deal creates an exciting new route to  market for the Netalogue Ecommerce platform making it more accessible to X3  partners and end users. Netalogue are also attending and sponsoring the Sage Summit next month at ExCel London on the 5th and 6th April 2017.

 

IMC Exploration (NEX:IMCP) 2p £2.6m

IMC announced the implementation of its work’s programme on its base metal licence area in the highly prospective South West Ireland.  The comprehensive exploration programme consists of geochemistry, geophysics and drilling. IMC holds numerous licences between the Tynagh and Silvermines deposits within this Irish Base Metal Province. These licences are highly prospective, lying proximal to the intersection of the ‘Navan-Silvermines Trend’ and ‘Limerick Trend’, the latter which hosts the deposits at Pallas Green and Kilbricken.

 

Head Chef:

Derren Nathan
0203 764 2344
derren.nathan@hybridan.com

*A corporate client of Hybridan LLP

Disclaimer

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.